These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 29084636

  • 1. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I, Zorzetto L, Frigo AC, Chiarion Sileni V, Alaibac M.
    Eur J Dermatol; 2017 Oct 01; 27(5):482-486. PubMed ID: 29084636
    [Abstract] [Full Text] [Related]

  • 2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 01; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 3. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P.
    JAMA Dermatol; 2015 Oct 01; 151(10):1103-9. PubMed ID: 26200476
    [Abstract] [Full Text] [Related]

  • 4. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A, Tsai K.
    Oncologist; 2017 Jul 01; 22(7):823-833. PubMed ID: 28526719
    [Abstract] [Full Text] [Related]

  • 5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
    J Am Acad Dermatol; 2014 Dec 01; 71(6):1102-1109.e1. PubMed ID: 25440439
    [Abstract] [Full Text] [Related]

  • 6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P.
    Br J Dermatol; 2015 Jan 01; 172(1):239-43. PubMed ID: 25040674
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A, Jain P, Fradley MG, Lenihan D, Gutierrez JM, Jain C, de Lima M, Barnholtz-Sloan JS, Oliveira GH, Dowlati A, Al-Kindi S.
    Cancer Med; 2021 Jun 01; 10(12):3862-3872. PubMed ID: 33982883
    [Abstract] [Full Text] [Related]

  • 9. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 May 01; 19(5):603-615. PubMed ID: 29573941
    [Abstract] [Full Text] [Related]

  • 10. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Morgado-Carrasco D, Moreno-Rivera N, Fustà-Novell X, García-Herrera A, Carrera C, Puig S.
    Melanoma Res; 2018 Jun 01; 28(3):256-257. PubMed ID: 29683894
    [No Abstract] [Full Text] [Related]

  • 11. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.
    Eur J Cancer; 2018 Sep 01; 101():229-235. PubMed ID: 30096703
    [Abstract] [Full Text] [Related]

  • 12. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM.
    Eur J Dermatol; 2016 Jun 01; 26(3):232-9. PubMed ID: 27019511
    [Abstract] [Full Text] [Related]

  • 13. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J.
    N Engl J Med; 2012 Nov 01; 367(18):1694-703. PubMed ID: 23020132
    [Abstract] [Full Text] [Related]

  • 14. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM.
    Eur J Dermatol; 2015 Apr 01; 25(2):177-80. PubMed ID: 25788221
    [Abstract] [Full Text] [Related]

  • 15. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V, Baric L, Cantagrel A, Di Palma M, Ederhy S, Paques M, Perlemuter G.
    Bull Cancer; 2021 May 01; 108(5):528-543. PubMed ID: 33812673
    [Abstract] [Full Text] [Related]

  • 16. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.
    Melanoma Res; 2014 Oct 01; 24(5):496-500. PubMed ID: 25185693
    [Abstract] [Full Text] [Related]

  • 17. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.
    N Engl J Med; 2019 Aug 15; 381(7):626-636. PubMed ID: 31166680
    [Abstract] [Full Text] [Related]

  • 18. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
    Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B.
    Lancet Oncol; 2017 Apr 15; 18(4):464-472. PubMed ID: 28268064
    [Abstract] [Full Text] [Related]

  • 19. Cutaneous effects of BRAF inhibitor therapy: a case series.
    Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.
    Ann Oncol; 2013 Feb 15; 24(2):530-537. PubMed ID: 23035153
    [Abstract] [Full Text] [Related]

  • 20. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M.
    J Eur Acad Dermatol Venereol; 2015 Jan 15; 29(1):61-8. PubMed ID: 24661317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.